title: Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities.
abstract: Core binding factor (CBF) is a heterodimeric protein complex involved in the transcriptional regulation of normal hematopoiesis. Mutations in CBF-encoding genes result in leukemogenic proliferative advantages and impaired differentiation of the hematopoietic progenitors. CBF molecular aberrations are responsible for approximately 20% of all adult acute myeloid leukemia (AML). Although CBF-AMLs are considered to have relatively good prognosis compared to other leukemia subtypes, they are a heterogeneous group of disorders and modern therapy frequently leads to relapse and the associated morbidity and mortality. Improvements in risk stratification and development of targeted therapies are needed for better outcomes. In this review we provide a brief overview of the molecular basis, prognostic categories and the advanced treatment strategies for CBF leukemias.
authors.affiliation: Bone Marrow Transplant & Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN.
authors.forename: Chandrima
authors.initials: C
authors.lastname: Sinha
authors.affiliation: Bone Marrow Transplant & Cellular Therapy, St Jude Children's Research Hospital, Memphis, TN. Electronic address: Lea.Cunningham@STJUDE.ORG.
authors.forename: Lea C
authors.initials: LC
authors.lastname: Cunningham
authors.affiliation: National Human Genome Research Institute, National Institutes of Health, Bethesda, MD. Electronic address: pliu@mail.nih.gov.
authors.forename: Paul P
authors.initials: PP
authors.lastname: Liu
mesh_terms: D000818:Animals; D050660:Core Binding Factors / Q000276:immunology*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology; D009154:Mutation; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D050660:Core Binding Factors